drugset / Trial / NCT00215722
XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination. This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.
Timeline
- Start
- 2005-07
- Primary completion
- —
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | — |